Matrix metalloproteinase (MMP)-1, -9 and -13 as prognostic factors in salivary gland cancer

Acta Oto-Laryngologica

Volumn 128, Issue 4, 2008, Pages 482-490

  Luukkaa, Heikki ^a   Klemi, Pekka ^a   Hirsimäki, Pirkko ^b   Vahlberg, Tero ^a   Kivisaari, Atte ^a,c   Kähäri, Veli Matti ^a,c   Grénman, Reidar ^a,b  

^a UNIVERSITY OF TURKU   (Finland)

^b TURKU UNIVERSITY HOSPITAL   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Acinic cell carcinoma; Adenoid cystic carcinoma; Matrix metalloproteinase; MMP; Mucoepidermoid carcinoma; Prognostic marker; Salivary duct carcinoma; Salivary gland cancer

Indexed keywords

BIOLOGICAL MARKER; COLLAGENASE 3; GELATINASE B; INTERSTITIAL COLLAGENASE; PARAFFIN;

ACINAR CELL CARCINOMA; ADENOID CYSTIC CARCINOMA; ADULT; AGED; ARTICLE; CANCER SURVIVAL; CARCINOMA; CLINICAL STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SALIVARY GLAND CANCER; SALIVARY GLAND DUCT CARCINOMA; STAINING; STATISTICAL SIGNIFICANCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SALIVARY GLAND NEOPLASMS; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 41349096268     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.1080/00016480801922895     Document Type: Article

References (26)

1. Vander Poorten VL. Salivary gland carcinoma - stepping up the prognostic ladder. Amsterdam: University of Amsterdam; 2002.
2. Finnish Cancer Registry, 15 August 2007. Available from URL: http://www.cancerregistry.fi/eng/statistics/
3. Luukkaa H, Klemi P, Leivo I, Koivunen P, Laranne J, Mäkitie A, et al. Salivary gland cancer in Finland 1991-96: an evaluation of 237 cases. Acta Otolaryngol (Stockh) 2005;125:207-14.
4. Eveson JW. Troublesome tumours 2: borderline tumours of salivary glands. J Clin Pathol 1992;45:369-77.
5. De S, Fenton JE, Jones AS. Matrix metalloproteinases and their inhibitors in non-neoplastic otorhinolaryngological disease. J Laryngol Otol 2005;119:436-42.
6. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;274:21491-4.
7. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003;92:827-39.
8. Ala-aho R, Kähäri VM. Collagenases in cancer. Biochimie 2005;87:273-86.
9. Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005;5:203-20.
10. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res 2005;11:5158-66.
11. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer 2002;97:432-8.
12. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat Med 1996;2:461-2.
13. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-61.
14. Murray GI, Duncan ME, Arbuckle E, Melvin WT, Fothergill JE. Matrix metalloproteinases and their inhibitors in gastric cancer. Gut 1998;43:791-7.
15. Ito T, Ito M, Shiozawa J, Naito S, Kanematsu T, Sekine I. Expression of the MMP-1 in human pancreatic carcinoma: relationship with prognostic factor. Mod Pathol 1999;12:669-74.
16. Johansson N, Vaalamo M, Grenman S, Hietanen S, Klemi P, Saarialho-Kere U, et al. Collagenase-3 (MMP-13) is expressed by tumor cells in invasive vulvar squamous cell carcinomas. Am J Pathol 1999;154:469-80.
17. Johansson N, Airola K, Grenman R, Kariniemi AL, Saarialho-Kere U, Kähäri VM. Expression of collagenase-3 (matrix metalloproteinase-13) in squamous cell carcinomas of the head and neck. Am J Pathol 1997;151:499-508.
18. Luukkaa M, Vihinen P, Kronqvist P, Vahlberg T, Pyrhönen S, Kähäri VM, et al. Association between high collagenase-3 expression levels and poor prognosis in patients with head and neck cancer. Head Neck 2006;28:225-34.
19. Riedel F, Gotte K, Schwalb J, Bergler W, Hormann K. Expression of 92-kDa type IV collagenase correlates with angiogenic markers and poor survival in head and neck squamous cell carcinoma. Int J Oncol 2000;17:1099-105.
20. Azuma M, Tamatani T, Fukui K, Yoshida H, Kamogashira T, Ogino K, et al. Role of plasminogen activators, metalloproteinases and the tissue inhibitor of metalloproteinase-1 in the metastatic process of human salivary-gland adenocarcinoma cells. Int J Cancer 1993;54:669-76.
21. Soini Y, Autio-Harmainen H. Synthesis and degradation of basement membranes in benign and malignant salivary gland tumours. A study by in situ hybridization. J Pathol 1993;170:291-6.
22. Freitas VM, Scheremeta B, Hoffman MP, Jaeger RG. Laminin-1 and SIKVAV a laminin-1-derived peptide, regulate the morphology and protease activity of a human salivary gland adenoid cystic carcinoma cell line. Oral Oncol 2004;40:483-9.
23. Kayano K, Shimada T, Shinomiya T, Nakai S, Hisa Y, Aoki T, et al. Activation of pro-MMP-2 mediated by MT1-MMP in human salivary gland carcinomas: possible regulation of pro-MMP-2 activation by TIMP-2. J Pathol 2004;202:403-11.
24. Nagel H, Laskawi R, Wahlers A, Hemmerlein B. Expression of matrix metalloproteinases MMP-2, MMP-9 and their tissue inhibitors TIMP-1, -2, and -3 in benign and malignant tumours of the salivary gland. Histopathology 2004;44:222-31.
25. Westernoff TH, Jordan RC, Regezi JA, Ramos DM, Schmidt BL. Beta-6 Integrin, tenascin-C, and MMP-1 expression in salivary gland neoplasms. Oral Oncol 2005;41:170-4.
26. O-Charoenrat P, Rhys-Evans P, Eccles S. A synthetic matrix metalloproteinase inhibitor prevents squamous carcinoma cell proliferation by interfering with epidermal growth factor receptor autocrine loops. Int J Cancer 2002;100:527-33.